BACKGROUND: Thyroid hormones regulate many different physiological processes in different tissues in vertebrates. Most of the actions of thyroid hormones are mediated by the thyroid hormone receptor (TR), which is a member of the nuclear receptor superfamily of ligand-activated transcription regulators. There are two different genes that encode two different TRs, TR alpha and TR beta, and these two TRs are often co-expressed at different levels in different tissues. Most thyroid hormones do not discriminate between the two TRs and bind both with similar affinities. RESULTS: We have designed and synthesized a thyroid hormone analog that has high affinity for the TRs and is selective in both binding and activation functions for TR beta over TR alpha. The compound, GC-1, was initially designed to solve synthetic problems that limit thyroid hormone analog preparation, and contains several structural changes with respect to the natural hormone 3,5,3'-triiodo-L-thyronine (T3). These changes include replacement of the three iodines with methyl and isopropyl groups, replacement of the biaryl ether linkage with a methylene linkage, and replacement of the amino-acid sidechain with an oxyacetic-acid sidechain. CONCLUSIONS: The results of this study show that GC-1 is a member of a new class of thyromimetic compounds that are more synthetically accessible than traditional thyromimetics and have potentially useful receptor binding and activation properties. The TR beta selectivity of GC-1 is particularly interesting and suggests that GC-1 might be a useful in vivo probe for studying the physiological roles of the different thyroid hormone receptor isoforms.
BACKGROUND: Thyroid hormones regulate many different physiological processes in different tissues in vertebrates. Most of the actions of thyroid hormones are mediated by the thyroid hormone receptor (TR), which is a member of the nuclear receptor superfamily of ligand-activated transcription regulators. There are two different genes that encode two different TRs, TR alpha and TR beta, and these two TRs are often co-expressed at different levels in different tissues. Most thyroid hormones do not discriminate between the two TRs and bind both with similar affinities. RESULTS: We have designed and synthesized a thyroid hormone analog that has high affinity for the TRs and is selective in both binding and activation functions for TR beta over TR alpha. The compound, GC-1, was initially designed to solve synthetic problems that limit thyroid hormone analog preparation, and contains several structural changes with respect to the natural hormone 3,5,3'-triiodo-L-thyronine (T3). These changes include replacement of the three iodines with methyl and isopropyl groups, replacement of the biaryl ether linkage with a methylene linkage, and replacement of the amino-acid sidechain with an oxyacetic-acid sidechain. CONCLUSIONS: The results of this study show that GC-1 is a member of a new class of thyromimetic compounds that are more synthetically accessible than traditional thyromimetics and have potentially useful receptor binding and activation properties. The TR beta selectivity of GC-1 is particularly interesting and suggests that GC-1 might be a useful in vivo probe for studying the physiological roles of the different thyroid hormone receptor isoforms.
Authors: Sabine Borngraeber; Mary-Jane Budny; Grazia Chiellini; Suzana T Cunha-Lima; Marie Togashi; Paul Webb; John D Baxter; Thomas S Scanlan; Robert J Fletterick Journal: Proc Natl Acad Sci U S A Date: 2003-12-12 Impact factor: 11.205
Authors: Alexandre Suman de Araujo; Leandro Martínez; Ricardo de Paula Nicoluci; Munir S Skaf; Igor Polikarpov Journal: Eur Biophys J Date: 2010-05-30 Impact factor: 1.733
Authors: Marta Szydlowska; Monica Pibiri; Andrea Perra; Elisabetta Puliga; Sandra Mattu; Giovanna M Ledda-Columbano; Amedeo Columbano; Vera P Leoni Journal: Gene Expr Date: 2017-04-13
Authors: M O Ribeiro; S D Carvalho; J J Schultz; G Chiellini; T S Scanlan; A C Bianco; G A Brent Journal: J Clin Invest Date: 2001-07 Impact factor: 14.808
Authors: Daniel F Vatner; Dirk Weismann; Sara A Beddow; Naoki Kumashiro; Derek M Erion; Xiao-Hui Liao; Gary J Grover; Paul Webb; Kevin J Phillips; Roy E Weiss; Jonathan S Bogan; John Baxter; Gerald I Shulman; Varman T Samuel Journal: Am J Physiol Endocrinol Metab Date: 2013-05-07 Impact factor: 4.310
Authors: Mark D Erion; Edward E Cable; Bruce R Ito; Hongjian Jiang; James M Fujitaki; Patricia D Finn; Bao-Hong Zhang; Jinzhao Hou; Serge H Boyer; Paul D van Poelje; David L Linemeyer Journal: Proc Natl Acad Sci U S A Date: 2007-09-18 Impact factor: 11.205